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Introduction: Pediatric oncology is often considered as a field in which research and care are
highly integrated. We believe that this integration can be seen as a so‐called Learning Health
System, a system in which research is considered an important means to continuously improve
the practice of care. In order to substantiate our assumption of pediatric oncology as an LHS,
we will analyze so‐called “best available treatment protocols.” These protocols always contain
research elements, even if themain goal of these protocols is to treat children diagnosed with
cancer.
Methods: We will analyze the implications for ethical review and informed consent if these
protocols had to function as exponents of pediatric oncology an LHS.
Results: An analysis of best available treatment protocols teaches us how these protocols
integrate care and research and how these protocols can be seen as exponents of a system where
care and research need no longer be sharply distinct practices.
Discussion: Further intervention in the field of pediatric oncology is essential to also meet the
requirements for an ethically responsible LHS.
Conclusion: Best available treatment protocols, which combine research and care, can be
seen as examples of pediatric oncology as an LHS. However, in order to prevent that research
elements in these protocols will be overlooked, we will have to find new ways to accommodate
for the oversight of these protocols, such as multifaceted review and risk‐adapted approaches.
Moreover, informed consent process must be changed in order for patients to understand how
care and research are integrated in these protocols.
KEYWORDS
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Pediatric oncology is often considered as a field where research and
care are highly integrated.1-4 First, research is considered as a funda-
mental aspect of pediatric oncology. Pediatric oncologists have a- - - - - - - - - - - - - - - - - - - - - - - - - - -
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of children with cancer, leading to a mindset of continuous learning
from current practice.3,4 In addition, parents and (older) children are
highly motivated to help to improve the diagnosis and treatment of
childhood cancer in general.5 Second, in many countries, children with
cancer are registered in cooperative group databases and/or in
national cancer registries. These databases may be used for epidemio-
logical studies and for selecting disease groups where improvements- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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What is known
• Pediatric oncology is often seen as a practice in which
care and research are intertwined
What is new
• So–called best available treatment protocols are
examples that clearly illustrate the integration of care
and research.
2 of 6 COMMENTARYare needed, followed by guideline development and evaluation.6 Third,
for many diseases, there are collaborative group or international
(eg, European or even TransAtlantic) phase III studies, and sometimes
also open phase I/II studies.7 Children with cancer often participate
in more than one of these studies, for instance, because they experi-
ence a relapse or because they also participate in intervention studies
in supportive care, on psycho‐social interventions and the like. Fourth,
children often participate in studies that are added to best available
treatment protocols or phase I‐III studies. These “add on” studies run
from laboratory studies with left over tumor material to biomarker
development and to implementation of new radiological techniques.3,5
Fifth and finally, for many cancers, children will be treated according
to so‐called best available treatment protocols.8 These protocols
provide children with the best currently available treatment, which is
usually an optimized version of the previous treatment regimen.9
While evidence resulting from one or more randomized controlled
trials may be lacking, the protocols are developed based on data
collection, experience, and (inter)national consensus among pediatric
oncologists.9
The enormous drive to improve the field by integrating learning
activities in daily care and treatment, the high rate of research partici-
pation, and in particular the best available treatment protocols that
truly integrate care and research may turn pediatric oncology into a
so‐called Learning Health System (LHS), a system in which research
is embedded in the practice of care to ensure “the best evidence for
the collaborative healthcare choices of each patient and provider”
and “innovation, quality, safety, and value in health care.”10 The LHS
starts from the presumption that the practices of research and care
are no longer sharply distinct as they usually are.2,10,11 In an LHS, both
research and care activities aim to yield generalizable knowledge, are
systematically performed, subject patients to procedures and interven-
tions that are not (only) in their own interests, which also may entail
high risks, and assign treatments according to protocols.2 Giving up
the distinction has implications for ethical review and informed
consent procedures since traditionally, research practices have been
subject to more stringent (inter)national laws and ethics regulations
than other medical learning activities involving human beings, such as
quality improvement studies.2,11,12
Thus far pediatric oncology has not been officially coined as an
LHS, and proper analyses are lacking. To start this analysis of pediatric
oncology as an LHS, in this paper, we will ethically analyze the best
available treatment protocols. We will consider how and to what extent
they contribute to the conception of pediatric oncology as an LHS. In
particular, we will focus on the implications for ethical review and
informed consent processes.2 | ANALYSIS
2.1 | Best available treatment protocols and the LHS
In general, best available treatment protocols not only prescribe how
childhood cancers ought to be treated but also include data collection
regarding diagnosis, risk‐group stratification, treatment, and outcome
in order to improve the survival of present and future children with
cancer.2,8 The protocol may also involve centralized pathology orradiology review. Since the new treatment protocol is established on
the basis of prior experience and (inter)national consensus, but not
(always) on conclusive evidence (for example, from randomized
controlled trials), pediatric oncologists typically use data‐collection
methods and for instance early stopping rules to secure the safety
and efficacy of the patients enrolled in the new treatment protocol.
Data collection in subsequent single‐arm studies rather than conclu-
sive evidence in the form of randomized trials is also inevitable in some
childhood cancers given their rarity. But it is not merely the data
collection related to these treatment protocols that makes them
subject to research. It is also, or perhaps in particular, the uncertainty
over the relative merits of new treatment strategy that is already consid-
ered the standard of care. This uncertainty is typically underemphasized
since pediatric oncologists consider the previous protocol as outdated
and no longer as the best current treatment once a new protocol has
been developed.8 There is often a strong belief that the treatment
recommended in the latest version of the “best available treatment”
protocol should not be withheld from children, since it is considered
the best available medical alternative. There are however examples
where this in hindsight did not appear to be the case. For instance,
the Dutch Childhood Oncology Group Acute Lymphoblastic
Leukemia‐7 protocol resulted in worse outcome compared to the
Berlin‐Frankfurt‐Münster study it was based upon and was stopped
prematurely.72.2 | Review
Ethical review of best available treatment protocols currently depends
on its categorization. In Figure 1, we describe 4 examples of classifica-
tion of (Dutch) best available treatment protocols. The protocol in the
first example underwent ethical review since it was classified as
research; the protocols in the other examples were exempted from
review since they were classified as care. Classification of best
available treatment protocols thus apparently varies. But even if we
were able to label these protocols in a more uniform way, applying
one label seems to be a sheer impossibility. Instead, we propose to
more explicitly remove the boundary between research and care for
these protocols and to require ethical scrutiny for all best available
treatment protocols, regardless of the question whether the protocol
can be classified as research or care.
FIGURE 1 Examples of best availabletreatment protocols
COMMENTARY 3 of 6
4 of 6 COMMENTARY2.3 | Informed consent
Another ethical challenge is the informed consent process for best
available treatment protocols. First, children and their parents cannot
meaningfully opt out of best available treatment protocols. Physicians
are usually reluctant to provide patients with the treatment of the
previous protocol as it is considered outdated.8 Although many
jurisdictions in general will allow children and their parents to refuse
treatment, patients cannot refuse the research component since this
is an inherent aspect of the protocol. In other words, voluntary
informed consent for these protocols is compromised.13
Second, when a best available treatment protocol is classified as
care, it may not be immediately clear to parents and their children that
the protocol contains research elements. If it is classified as research, it
is problematic that consent for the standard treatment is formulated
through the lens of a research perspective. Then elements of care
may be underemphasized. Thus, the hybrid status of these protocols
may influence the way in which these protocols are presented and
understood.3 | DISCUSSION
An analysis of best available treatment protocols teaches us how these
protocols integrate care and research and how these protocols can be
seen as exponents of a system where care and research need no longer
be sharply distinct practices. However, further intervention in the field
of pediatric oncology is essential to also meet the requirements for an
ethically responsible LHS.3.1 | Ethical review
We propose a twofold review strategy for ethical review. First, we
should create a multifaceted review system. Largent and colleagues
have recently proposed a similar system of research ethics review
for comparative effectiveness studies in an LHS.1 In their model,
several advisory boards, ethics committees, scientific committees,
and even patient advisory boards review and approve research pro-
tocols, depending on the level of risks involved. Translated to pediat-
ric oncology as an LHS, we may adopt a system for pediatric
oncology in which the number of reviewing bodies will increase
but formal ethics review by the Research Ethics Committee (REC)
will decrease, in particular for studies with low risks (see the second
tier of our approach described below). In pediatric oncology, we may
think of a first round of internal review by scientific and ethical com-
mittees consisting of peers. They may determine that further review
is essential, but also that full review by an REC would be overly
demanding. One might object that this round of internal peer review
creates potential conflicts of interest. However, currently, the
research review system largely depends on the discretion of individ-
ual researchers to submit their protocols for review to RECs. There-
fore, a first layer of internal review may lead to intensified review of
the content of protocols.
Second, we should take a more risk‐adapted approach,14 requir-
ing more stringent or full review for protocols that contain changes
that are highly innovative or substantially deviate from the currentstandard treatment, such as in examples 1 and 2. But for other
protocols ethics, review can be less stringent. Although in pediatric
oncology, almost all treatments are high‐risk treatments, this does
not imply that full review is always essential. Usually best available
treatment protocols are based on years of experience. They are not
first in man studies or entirely new treatment strategies. Moreover,
in principle, there are sound reasons to change current protocols. In
a true Learning Health care System, the transition from the one
protocol to the next may also be more continuous. Pediatric
oncologists do not have to postpone submission to RECs until a
protocol has been substantially changed, but can make continuous
changes where necessary which are continuously being assessed.
Hypothetically, we may then think of some best available treatment
protocols as so‐called low‐intervention trials as defined in the new
EU regulation.15 Low‐intervention trials may be subjected to “less
stringent rules, as regards monitoring, requirements for the contents
of the master file and traceability of investigational medicinal prod-
ucts.”15 In order to assist RECs, a revised version of the EU
regulation may introduce the label “best available treatment proto-
cols” and compare it to the exceptions in this regulation for low‐
intervention trials, which would be a first step in the recognition of
best available treatment protocols.
This approach to the review of best available treatment protocols
may prevent both that research elements with more than minimal risks
are overlooked and that the interests of patients are overprotected
when the risks are minimal and the protocol is predominantly care
orientated. At the same time, if risk‐adapted approaches are adopted,
other ethical oversight protection mechanisms will have to play a role
to ensure scientific validity and that patients are not exposed to
unreasonable risks. For instance, it will then be essential to ensure
quality of data, monitoring of the approved protocol by Data and
Safety Monitoring Boards, and scientific validity by means of clearly
formulated hypotheses and prospectively defined statistical plans,
and to formulate stopping rules.3.2 | Informed consent
Best available treatment protocols may lead to compromises to
voluntary informed consent, which cannot be easily mitigated. But
they may be considered as acceptable when the social value of the
study is compelling and the study is the best available medical alter-
native for the child. At the same time, the level of understanding of
best available treatment protocols can be improved. If there were
regulatory oversight for hybrid protocols, physicians might use an
integrated form of consent.16 They might explain that even though
the treatment is considered the best available alternative according
to the medical professional standard, its relative merits may still be
uncertain. In the same vein, a form of “scientific citizenship”17 might
be warranted: In order to foster the autonomy of parents and their
children, they should be informed about the pervasiveness of
research and its sometimes inextricable link with care. It has been
argued that patients in an LHS should sometimes accept that they
participate in widely accepted research activities without their
explicit informed consent.11 Instead, we think that scientific citizen-
ship would require that patients are meaningfully engaged, so that
COMMENTARY 5 of 6researchers and patients recognize that they collectively generate
knowledge to improve the field.4 | CONCLUSION
Best available treatment protocols, which combine research and care,
can be seen as examples of pediatric oncology as an LHS. However,
in order to prevent that research elements in these protocols will be
overlooked, we will have to find new ways to accommodate for the
oversight of these protocols, such as multifaceted review and
risk‐adapted approaches. Moreover, since research elements are
embedded in the treatment of patients, even in protocols that are
predominantly care orientated, oversight systems may want to accom-
modate for informed consent processes for these protocols, in which
patients are meaningfully engaged. Patients and their parents have to
understand that research and care in pediatric oncology may be inex-
tricably intertwined.
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